Manufactured by Sunovion Pharmaceuticals Inc. (Fort Lee, New Jersey) – Latuda (lurasidone HCl) tablets – have just been approved by the US FDA for the treatment of adults with schizophrenia.
Affecting about 1 percent of the US population (ages 18 years and older) in a given year, schizophrenia’s most prominent symptoms include hallucinations, delusions, disordered thinking and behavior and suspiciousness. The most common type of hallucination is hearing voices that other people don’t hear.
Clinical trials of Latuda reported the most common adverse reactions as drowsiness, feelings of restlessness and the urge to move (akathisia), nausea, movement abnormalities such as tremors, slow movement, or muscle stiffness (Parkinsonism), and agitation.
Belonging in the atypical antipsychotic class of drugs, Latuda contains a boxed warning alerting prescribers to an increased risk of death associated with off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis.